2023 ESC Guidelines for the management of cardiomyopathies

Brève description

The objective of this guideline is to help healthcare professionals diagnose and manage patients with cardiomyopathies of all ages according to the best available evidence and to provide a practical diagnostic and treatment framework for patients and their relatives. This is a new guideline, not an update of existing guidelines, with the exception of the section on hypertrophic cardiomyopathy (HCM), in which we have provided a focused update to the 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. As such, most of the recommendations in this guideline are new. It is beyond the scope of this guideline to provide detailed descriptions and recommendations for each individual cardiomyopathy phenotype; instead, the aim is to provide a guide to the diagnostic approach to cardiomyopathies, highlight general evaluation and management issues, and signpost the reader to the relevant evidence base for the recommendations.

Groupe cible

Médecins, Infirmiers/infirmières, Scientifiques

Spécialité médicale

Médecine interne générale, Gynécologie et obstétrique, Chirurgie cardiaque et vasculaire thoracique, Cardiologie, Pédiatrie, Génétique médicale, Pathologie, Médecin praticien

Catégorie du guide

Diagnostic, Traitement, Prévention, Evaluation, Gestion/management, Dépistage, Conseil psychologique

Groupe cible de patients

Classe d'âge: Nouveau-nés (jusqu’à 1 mois), Nourrissons, Enfants en bas âge, Enfants, Adolescents (13-18 ans), Adultes
Sexe: Masculin, Féminin

Origine

Repris

Domaine d'application

National, Européen, International

Secteur

Les deux/intersectoriel

Langue originale

Anglais

Publié en

2023